

Zelira Therapeutics Ltd

12:45 28 Jan 2020

Zelira Therapeutics and US Parkinson's Foundation collaborate for medicinal cannabis survey

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB: ZLDAF) will collaborate with the Parkinson's Foundation in the US to gather insights from people living with Parkinson's Disease about their understanding of and use of medical cannabis and hemp-derived therapies.

Zelira and the Parkinson's Foundation will consult on the development of a survey tool to be sent to people with the diseases to understand why and how they are using medical cannabis and hemp-derived CBD products.

They will review the results as they relate to a possible future clinical trial on the safety and efficacy of medical cannabis use by people with Parkinson's disease.

Separately, Zelira will also incorporate survey insights to inform future development of clinically validated medical cannabis and hemp-derived CBD medicines for people with Parkinson's disease, and provide guidance to people with Parkinson's regarding various cannabinoid-based and hemp-derived CBD treatment alternatives.

"Essential insights"

Zelira founder and chairman Osagie Imasogie said: "Our Zelira Board is very supportive of this collaboration with the Parkinson's Foundation which will provide us with essential insights to inform our product development to address the specific needs of people with Parkinson's disease.

"This effort is consistent with our focus on patients and our desire to provide them with as many treatment options as possible."

Chief business officer Tom Borger said there was a lack of definitive studies informing clinicians and patients with Parkinson's about the safety and efficacy of medical cannabis.

He said: "One of the objectives of the survey and this collaboration is to provide guidance to people with Parkinson about the need for clinically validated medical marijuana and hemp-derived CBD medicines that might address their symptoms."

Medical cannabis

Parkinson's Foundation (US) president and chief executive officer John Lehr said: "Many people with Parkinson's disease are seeking help with their symptoms by trying various forms of medical cannabis.

"The volume and frequency of questions Parkinson's Foundation receive from people with Parkinson's regarding the safety and impact of medical cannabis

Price: 0.058

Market Cap: \$56.05 m

1 Year Share Price Graph



Share Information

Code: ZLD

Listing: ASX

52 week High Low
0.091 0.022

Sector: Cannabis

Website: www.zeldatherapeutics.com

Company Synopsis:

Zelira Therapeutics Ltd (ASX:ZLD) is a medicinal cannabis company focused on first-in-class human clinical trials for insomnia, autism and opioid reduction.

action@proactiveinvestors.com.au

and CBD has led us to examine this public health issue more fully, and to seek collaborations with leaders in the field from academia, government, advocacy groups and industry to provide the most accurate information possible.

"Zelira Therapeutics, a leader in disease-specific medical cannabis therapeutics, has committed to helping people with Parkinson's understand the role that medical cannabis might play in managing their daily symptoms."

Parkinson's Disease

Parkinson's Disease is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the US, affecting nearly 1 million Americans and 10 million people worldwide.

There is no cure for the disease, which is associated with a progressive loss of motor control (eg shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (eg depression and anxiety).

The Parkinson's Foundation is focused on improving the care of sufferers and advancing research toward a cure.

Commercialisation plans

Zelira is working with world-leading researchers and organisations to develop branded cannabis products for the treatment of a variety of medical conditions and is undertaking human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the USA.

Other work includes pre-clinical research examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Zelira has also formed a strategic partnership with European medicinal cannabis group HAPA Pharm BV, to access EU good manufacturing practice (GMP) grade manufacturing capabilities and its German distribution network to provide a credible and rapid path to commercialisation for successful clinically validated formulations.

The company also has the ability to conduct clinical trials in the US and is establishing a national footprint across the country for the licensing of its products.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).